2023
Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey
Lu Y, Liu Y, Jastreboff A, Khera R, Ndumele C, Rodriguez F, Watson K, Krumholz H. Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey. Circulation Cardiovascular Quality And Outcomes 2023, 17: e010640. PMID: 37950677, PMCID: PMC10782930, DOI: 10.1161/circoutcomes.123.010640.Peer-Reviewed Original Research
2022
Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States
Lu Y, Liu Y, Krumholz HM. Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States. Journal Of The American Heart Association 2022, 11: e025545. PMID: 36172953, PMCID: PMC9673703, DOI: 10.1161/jaha.121.025545.Peer-Reviewed Original ResearchConceptsLow family incomeEligible populationUsual sourceHispanic adultsFinancial barriersEthnic disparitiesNutrition Examination Survey 2015Drug Administration labelingCross-sectional analysisFamily incomePercentage of adultsObese adultsNational HealthUS adultsSemaglutideEligibility criteriaSocial determinantsBlack adultsLarge proportionFinal analysisWeight lossHispanic individualsWhite individualsAdultsRisk reduction
2021
National Trends in Racial and Ethnic Disparities in Antihypertensive Medication Use and Blood Pressure Control Among Adults With Hypertension, 2011–2018
Lu Y, Liu Y, Dhingra LS, Massey D, Caraballo C, Mahajan S, Spatz ES, Onuma O, Herrin J, Krumholz HM. National Trends in Racial and Ethnic Disparities in Antihypertensive Medication Use and Blood Pressure Control Among Adults With Hypertension, 2011–2018. Hypertension 2021, 79: 207-217. PMID: 34775785, DOI: 10.1161/hypertensionaha.121.18381.Peer-Reviewed Original ResearchConceptsAntihypertensive medication usePoor hypertension controlOverall treatment rateLow control rateHypertension controlHypertension awarenessMedication useControl rateHispanic individualsEthnic differencesTreatment ratesBlack individualsGuideline-recommended medicationsBlood pressure controlWhite individualsNutrition Examination SurveyLow awareness rateAntihypertensive medicationsHypertensive peopleExamination SurveyIntensive medicationNational HealthAwareness rateEthnic disparitiesPressure controlTrends and geographical variation in population thriving, struggling and suffering across the USA, 2008–2017: a retrospective repeated cross-sectional study
Riley C, Herrin J, Lam V, Hamar B, Witters D, Liu D, Krumholz HM, Roy B. Trends and geographical variation in population thriving, struggling and suffering across the USA, 2008–2017: a retrospective repeated cross-sectional study. BMJ Open 2021, 11: e043375. PMID: 34261676, PMCID: PMC8281074, DOI: 10.1136/bmjopen-2020-043375.Peer-Reviewed Original ResearchConceptsPercentage of peopleCross-sectional studyWell-Being IndexMarked geographical variationNational HealthRetrospective analysisUS populationCross-sectional sampleLife evaluationGeographical disparitiesGreater improvementCantril SelfCurrent life satisfactionGeographical variationLife optimismNational averageInterventionConceptions of healthHealthPercentageContemporary National Patterns of Eligibility and Utilization of Novel Cardioprotective Anti‐hyperglycemic agents in Type 2 Diabetes
Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R. Contemporary National Patterns of Eligibility and Utilization of Novel Cardioprotective Anti‐hyperglycemic agents in Type 2 Diabetes. Journal Of The American Heart Association 2021, 10: e021084. PMID: 33998258, PMCID: PMC8403287, DOI: 10.1161/jaha.121.021084.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersBlood GlucoseCardiovascular DiseasesDiabetes Mellitus, Type 2Drug UtilizationEligibility DeterminationFemaleGlucagon-Like Peptide-1 ReceptorGuideline AdherenceHeart Disease Risk FactorsHumansIncretinsMaleMiddle AgedNutrition SurveysPractice Guidelines as TopicPractice Patterns, Physicians'Risk AssessmentSodium-Glucose Transporter 2 InhibitorsTime FactorsTreatment OutcomeUnited StatesConceptsSGLT-2 inhibitorsType 2 diabetes mellitusAtherosclerotic cardiovascular diseaseChronic kidney diseaseLarge clinical trialsGLP-1RAsDiabetes mellitusCardiovascular diseaseHeart failureKidney diseaseClinical trialsHigh-risk atherosclerotic cardiovascular diseaseGLP-1RA useAmerican Diabetes AssociationNutrition Examination SurveyAnti-hyperglycemic agentsPublic health benefitsComplex survey designCardiovascular riskGuideline recommendationsDiabetes AssociationExamination SurveyProtective therapyNational HealthAmerican College
2018
Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study
Khera R, Lu Y, Lu J, Saxena A, Nasir K, Jiang L, Krumholz HM. Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study. The BMJ 2018, 362: k2357. PMID: 29997129, PMCID: PMC6039831, DOI: 10.1136/bmj.k2357.Peer-Reviewed Original ResearchConceptsACC/AHA guidelinesDiagnosis of hypertensionAge groupsHypertension guidelinesAHA guidelinesTreatment patternsCurrent guidelinesACC/AHA hypertension guidelinesHeart Association hypertension guidelinesCurrent treatment patternsIntensification of treatmentPrevalence of hypertensionNutrition Examination SurveyYears age groupUS National HealthYear old adultsSame age groupRetirement Longitudinal StudyAntihypertensive treatmentExamination SurveyNational HealthHypertensionAmerican CollegeChina HealthOlder adults
2017
Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey
Su M, Zhang Q, Bai X, Wu C, Li Y, Mossialos E, Mensah GA, Masoudi FA, Lu J, Li X, Salas-Vega S, Zhang A, Lu Y, Nasir K, Krumholz HM, Jiang L. Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey. The Lancet 2017, 390: 2559-2568. PMID: 29102087, DOI: 10.1016/s0140-6736(17)32476-5.Peer-Reviewed Original ResearchConceptsPrimary health care sitesNationwide cross-sectional surveyAntihypertensive medicationsPrimary health carePrescription patternsCross-sectional surveyHealth care sitesHealth centersVillage clinicsPrimary health care providersCommunity health stationsBurden of hypertensionCommunity health centersHealth careCAMS Innovation FundHealth care providersHigh-cost medicationsTownship health centersBlood pressureFamily Planning CommissionMedication costsAffordable medicationsNational HealthHealth stationsMedications
2015
Admission glucose and in-hospital mortality in patients with acute myocardial infarction, with and without diabetes, from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis
Zhao S, Murugiah K, Li X, Li J, Li N, Xu Z, Cheng C, Mao H, Wang Q, Krumholz H, Jiang L, Group O. Admission glucose and in-hospital mortality in patients with acute myocardial infarction, with and without diabetes, from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis. The Lancet 2015, 386: s43. DOI: 10.1016/s0140-6736(15)00624-8.Peer-Reviewed Original ResearchAcute myocardial infarctionBlood glucose concentrationHospital mortalityMyocardial infarctionChinese patientsMortality riskGlucose concentrationAcute Myocardial Infarction StudyProportion of patientsHospital mortality riskMyocardial Infarction StudyUS National HeartEuglycaemic patientsAdmission glucoseDiabetes statusFamily Planning CommissionHospital admissionPatient characteristicsGlucose categoriesClinical statusBlood InstituteNational HeartNational HealthCardiovascular diseaseRetrospective analysis
2011
Trends in Comorbidity, Disability, and Polypharmacy in Heart Failure
Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in Comorbidity, Disability, and Polypharmacy in Heart Failure. The American Journal Of Medicine 2011, 124: 136-143. PMID: 21295193, PMCID: PMC3237399, DOI: 10.1016/j.amjmed.2010.08.017.Peer-Reviewed Original ResearchConceptsProportion of patientsHeart failureSelf-reported heart failureHeart failure populationComorbid chronic conditionsNumber of comorbiditiesNutrition Examination SurveyCare of patientsPrevalence of disabilityPhenotype of patientsComplexity of patientsMedication useRecent patientsFunctional disabilityExamination SurveyFailure populationPhysical functionPrescription medicationsPatient preferencesChronic conditionsNational HealthPatient's abilityComorbiditiesPatientsOlder individuals
2010
Beyond insurance coverage: Usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination Survey
Spatz ES, Ross JS, Desai MM, Canavan ME, Krumholz HM. Beyond insurance coverage: Usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination Survey. American Heart Journal 2010, 160: 115-121. PMID: 20598981, PMCID: PMC3025407, DOI: 10.1016/j.ahj.2010.04.013.Peer-Reviewed Original ResearchConceptsTreatment of hypertensionNutrition Examination SurveyInsurance statusMedication treatmentExamination SurveyNational HealthUsual sourceAdult Treatment Panel III recommendationsJoint National Committee 7Multivariable logistic regression modelingInsurance coverageSeparate multivariable modelsChronic disease managementLogistic regression modelingHigh-quality careRace/ethnicityCardiovascular diseaseMultivariable modelStratified analysisHypertensionHypercholesterolemiaRegular sourceCareDisease managementIndependent effects